RLS Global AB (publ) (RLS.ST) Research

RLS Global AB (publ) is a Swedish medical technology firm that specializes in developing and commercializing therapeutic products for conditions within wound and oral care. Among its key offerings are ChloraSolv, a treatment specifically designed for chronic diabetic foot and leg ulcers in diabetic patients, and CariSolv, a unique gel employed for the removal of dental caries. Established in 1996, the company maintains its headquarters in Mölndal, Sweden.

Market snapshot

Symbol
RLS.ST
Price
$0.45
Day change
-0.89%
Market cap
$35.7M
P/E ratio
-1.27x
52-week range
0.446-0.446
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • AegirBio AB (publ) (AEGIR.ST)
  • Amniotics AB (publ) (AMNI.ST)
  • Coala-Life Group AB (publ) (COALA.ST)
  • CombiGene AB (publ) (COMBI.ST)
  • Diagonal Bio AB (publ) (DIABIO.ST)
  • Emplicure AB (publ) (EMPLI.ST)
  • FRISQ Holding AB (publ) (FRISQ.ST)
  • Kancera AB (publ) (KAN.ST)

Open RLS Global AB (publ) (RLS.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.